{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Akero Therapeutics, Inc.
Is Akero Therapeutics, Inc. technically bullish or bearish?
As of May 29, 2025, Akero Therapeutics, Inc. has shifted to a bullish trend, supported by strong indicators like bullish MACD and moving averages, with a year-to-date return of 94.21%, significantly outperforming the S&P 500.
Who are in the management team of Akero Therapeutics, Inc.?
As of March 2022, the management team of Akero Therapeutics, Inc. includes Mark Iwicki (Independent Non-Executive Chairman), Dr. Andrew Cheng (President and CEO), and several Independent Directors: Tomas Heyman, Kevin Bitterman, Seth Harrison, and Jane Henderson. This team is responsible for guiding the company's strategic direction and operations.
What does Akero Therapeutics, Inc. do?
Akero Therapeutics, Inc. is a biotechnology company focused on developing treatments for non-alcoholic steatohepatitis (NASH) to restore metabolic balance. It has a market cap of approximately $4.42 billion and reported a net loss of $71 million as of March 2025.
How big is Akero Therapeutics, Inc.?
As of Jun 18, Akero Therapeutics, Inc. has a market capitalization of $4.42 billion, with net sales of $0.00 million and a net profit of -$269.43 million over the last four quarters. The company reported shareholder's funds of $750.11 million and total assets of $825.89 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
